The prognostic impact of the platelet distribution width-to-platelet count ratio in patients with breast cancer

Hideya Takeuchi*, Miyuki Abe, Yohei Takumi, Takafumi Hashimoto, Ryoji Kobayashi, Atsushi Osoegawa, Michiy0 Miyawaki, Tatsuro Okamoto, Kenji Sugio

Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Oita, Japan

* takeuchi@oita-u.ac.jp

Abstract

Activated platelets promote tumor cell growth, angiogenesis, and invasion. Platelet activity can be inferred by platelet volume indices (PVIs), which include platelet distribution width (PDW), mean platelet volume (MPV), platelet distribution width-to-platelet count ratio (PDW/P), and mean platelet volume-to-platelet count ratio. Platelets and platelet-related markers, such as the platelet-to-lymphocyte ratio, have been found to be significant prognostic factors in patients with breast cancer. However, the role of PVIs for predicting survival in breast cancer remains unknown; hence, we performed this retrospective analysis of 275 patients with breast cancer. PVIs were compared with clinicopathological variables, and were assessed to identify independent indicators associated with disease-free survival (DFS) using the Cox proportional hazards model. An elevated PDW/P significantly correlated with age and HER2 status. Univariate analysis revealed that elevated PDW, MPV, and PDW/P as well as tumor size, nuclear grade, and lymph node involvement were significantly associated with inferior DFS rates (tumor size: \( p < 0.01 \); nuclear grade, lymph node involvement, PDW, MPV, and PDW/P: \( p < 0.05 \)). On multivariate analysis, a large tumor size and elevated PDW/P were significant prognostic factors for DFS, with hazard ratios of 3.24 (95% confidence interval [CI]: 1.24–8.47) and 2.99 (95% CI: 1.18–7.57), respectively (\( p < 0.05 \)). Our study is the first to reveal that an elevated PDW/P significantly reduces DFS in patients with breast carcinoma. Measuring the PDW/P is simple, relatively inexpensive, and almost universally available using routine blood counts; this makes it an attractive biomarker for improved risk assessment.

Introduction

Breast cancer is the commonest malignant disease among Japanese women, and is a frequent cause of cancer-related death [1, 2]. The conventional tumor node metastasis (TNM) staging system can predict the prognosis of breast cancer; however, clinical outcomes vary remarkably among patients with similar TNM stages [3]. Although molecular diagnostic tests such as Oncotype Dx and Mammaprint may be used to obtain additional prognostic information and
help guide clinical therapies in Europe and the United States, the Japanese National Health Insurance does not sustain their use in routine clinical practice owing to the high cost and regional availability of these kits [4]. Thus, identifying prognostic breast cancer biomarkers that are low-cost and easily obtainable via routine blood counts is of great importance.

Platelet activation has been shown to be common in cardiovascular diseases such as acute ischemic stroke, myocardial infarction, and renal artery stenosis [5]. Recently, more attention has been focused on the clinical significance of platelet activation in several malignancies [6]. Platelet-derived growth factor-receptor (PDGF-R) is involved in cancer invasion and metastases. Indeed, elevated PDGF and PDGF-R levels in several tumor tissues are negative prognostic factors [7–11]. We have also shown that platelet-related markers, such as the platelet-to-lymphocyte ratio (PLR), are significant prognostic factors in patients with breast cancer [12,13].

Larger platelets store more granules and receptors, and adhere more rapidly than smaller ones. Thus, the platelet’s activity is more accurately represented by their size, not count [14]. Platelet size can be inferred from the platelet volume indices (PVIs), including the platelet distribution width (PDW), mean platelet volume (MPV), platelet distribution width-to-platelet count ratio (PDW/P), and mean platelet volume-to-platelet count ratio (MPV/P). PDW reflects the variation and heterogeneity in platelet size, and is used in the differential diagnosis of thrombocytopenia [15]. MPV is an indicator of activated platelets and is linked to various inflammatory conditions [16]. Both PDW and MPV are routinely measured by automated common blood count analyzers. Recent studies revealed that MPV and MPV/P levels are associated with poor prognoses in esophageal, breast, hepatocellular, and lung carcinomas [17–21]. However, to the best of our knowledge, the prognostic values of PDW and PDW/P in patients with breast cancer has not been reported.

Hence, the purpose of our study was to evaluate the effect of the PVIs on the DFS rates of patients with localized breast cancer to determine their prognostic significance.

Patients and methods

Patients

This was a retrospective study of 327 patients with histologically confirmed breast cancer who underwent surgery at the Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine between April 2006 and December 2016. Fifth-two patients who were excluded from our analysis because of distant metastases at initial presentation (n = 8), carcinoma in situ (n = 25), bilateral breast carcinoma (n = 7), male breast carcinoma (n = 2), medical anticoagulant treatment (n = 1), and insufficient laboratory data (n = 9). Ultimately, 275 patients with localized breast cancer were eligible for this study. As previously described in detail [12,13], adjuvant therapy was administered according to the St. Gallen recommendations [22]. Follow-up care was performed at regular intervals (3-month intervals during years 1-5 and at 6-month intervals during years 5–10 post-diagnosis). Follow-up investigations included clinical examinations, laboratory data analyses (carcinoembryonic antigen and carbohydrate-antigen 15–3 levels), and radiological assessment (computed tomography and mammography) every 12 months during years 1–10 post-diagnosis.

Pathological characteristics

As described previously [12,13], pathological data were reviewed to determine the tumor size, nuclear grade, lymph node status, hormone receptor status and human epidermal growth factor receptor 2 (HER2) status. Estrogen and progesterone receptor statuses were evaluated via immunohistochemistry (IHC). Tumors with nuclear expression scores above 0 were considered positive. HER2 status was assessed via IHC or fluorescence in situ hybridization and was
considered positive upon obtaining either an IHC score of 3 or at least a 2.2-fold stronger HER2 signal relative to the CEP-17 signal in the tumor cells [23].

**PVI measurement**

Blood samples were obtained via peripheral venous puncture before the initiation of any treatment modality. PVIs were measured routinely with an automatic nephelometer (XN-9000; Sysmex Corporation, Kobe, JAPAN) according to the manufacturer’s instructions.

The PDW/P and MPV/P were calculated as the absolute platelet distribution width and platelet mean volume count, respectively, divided by the platelet count (10^4/mL). The ideal cutoff value for PVI was determined by receiver operating characteristics (ROC) curve analysis.

**Statistical analysis**

The primary endpoint of the study was DFS defined as the interval between the date of initial treatment and the first observation of disease relapse. The descriptive statistics are presented as means ± standard deviation. The between-group differences were determined using Student’s t-tests.

Survival curves were estimated using the Kaplan–Meier method. All variables were assessed using a Cox proportional hazards model to identify any independent variables associated with DFS. Hazard ratios (HRs) estimated using Cox analysis were reported as relative risks with their corresponding 95% confidence intervals (CIs). All statistical analyses were performed using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). EZR is a modified version of R Commander designed to include the statistical functions frequently used in biostatistics [24]. A p-value <0.05 was considered significant.

**Data collection and ethics compliance**

This retrospective study, including the opt-out consent method, was approved by the institutional ethics review board (the clinical research board of Oita University, institutional ID: 1294). All medical data from the participants were anonymized and compiled. The study plan and choice to freely refuse participation were announced through the hospital bulletin at the Oita University Faculty of Medicine. Patients were considered to have consented to the study if they did not refuse participation.

**Results**

**Patients’ characteristics**

The basic characteristics of the enrolled patients are summarized in Table 1. The median age was 64.5 (range: 31–92 years) at the time of diagnosis. Patients were divided into two groups with regards to each of PDW, MVP, PDW/P, and MVP/P according to the cutoff values established by ROC analysis.

ROC analysis showed that the optimal cutoff values for DFS were 15.3, 9.0, 0.59, and 0.35 for the PDW, MPV, PDW/P, and MVP/P, respectively (Table 2).

The associations between PVIs and clinicopathological variables are shown in Tables 3 and 4. The PDW correlated with tumor size, estrogen receptor status, and progesterone receptor status. The PDW/P correlated with age and HER2 status (p<0.05).
Survival

After a median follow-up duration of 45 months, 25 patients (9.1%) had experienced recurrence. Univariate analysis revealed significant impacts of tumor size, nuclear grade, lymph node involvement, PDW, MPV, and PDW/P on DFS. Other variables were not found to be significantly correlated with DFS. Thus, variables that showed a p-value < 0.05 on univariate analysis were subjected to multivariate analysis. On multivariate analysis, large tumor size and

Table 1. Basic characteristics of the enrolled patients.

| Variables                  | No. (%) |
|----------------------------|---------|
| Age (years)                |         |
| <50                        | 33 (12) |
| ≥50                        | 242 (88)|
| Tumor size (mm)            |         |
| <20                        | 179 (65)|
| ≥20                        | 96 (35) |
| Nuclear grade              |         |
| 1                          | 121 (44)|
| 2, 3                       | 141 (51)|
| Unknown                    | 13      |
| Lymph node involvement     |         |
| Negative                   | 207 (75)|
| Positive                   | 68 (25) |
| Estrogen receptor          |         |
| Negative                   | 69 (25) |
| Positive                   | 206 (75)|
| Progesterone receptor      |         |
| Negative                   | 114 (42)|
| Positive                   | 161 (58)|
| HER2                       |         |
| Negative                   | 230 (84)|
| Positive                   | 39 (14) |
| Unknown                    | 6       |
| PDW                        |         |
| <15.3                      | 227 (83)|
| ≥15.3                      | 48 (17) |
| MPV                        |         |
| <9                         | 58 (21) |
| ≥9                         | 217 (79)|
| PDW/P                      |         |
| <0.59                      | 169 (62)|
| ≥0.59                      | 106 (38)|
| MPV/P                      |         |
| <0.35                      | 62 (23) |
| ≥0.35                      | 213 (77)|

Abbreviations: No, number; HER2, human epidermal growth factor receptor 2; PDW, platelet distribution width; MPV, mean platelet volume; PDW/P, platelet distribution width-to-platelet count ratio; MPV/P, mean platelet volume-to-platelet count ratio

https://doi.org/10.1371/journal.pone.0189166.t001

Survival

After a median follow-up duration of 45 months, 25 patients (9.1%) had experienced recurrence. Univariate analysis revealed significant impacts of tumor size, nuclear grade, lymph node involvement, PDW, MPV, and PDW/P on DFS. Other variables were not found to be significantly correlated with DFS. Thus, variables that showed a p-value < 0.05 on univariate analysis were subjected to multivariate analysis. On multivariate analysis, large tumor size and
elevated PDW/P were significantly correlated with poor prognosis for DFS, with HRs of 3.24 (95% CI: 1.24–8.47, p < 0.05), and 2.99 (95% CI: 1.18–7.57, p < 0.05), respectively (Table 5).

The DFS rate was significantly lower in the elevated PDW/P group than in the low PDW/P group (5-year survival, 81.3% vs. 89.9%, respectively; p < 0.05) (Fig 1).

**Discussion**

Platelets are rich in growth factors such as PDGF [7–11], transforming growth factor-β [25], and platelet-derived endothelial cell growth factor [26]. These platelet-derived growth factors are often produced in large quantities by cancer cells and contribute to their progression [25]. In breast cancer, PDGF beta receptor expression correlates with unfavorable clinicopathological characteristics and survival [10]. Kang DW et al. showed that PDGF contributes to the aggressiveness of breast cancer cells by the NFkB signaling pathway [11]. Elevated platelet

Table 2. Receiver operating characteristics analyses of platelet volume indices in breast cancer patients.

| Variables | Cut-off value | AUC (95%CI)       | Specificity | Sensitivity |
|-----------|---------------|------------------|-------------|-------------|
| PDW       | 15.3          | 0.61 (0.47–0.74) | 0.85        | 0.4         |
| MPV       | 9.0           | 0.62 (0.49–0.76) | 0.79        | 0.48        |
| PDW/P     | 0.59          | 0.58 (0.46–0.7)  | 0.64        | 0.6         |
| MPV/P     | 0.35          | 0.56 (0.41–0.7)  | 0.79        | 0.4         |

Abbreviations: AUC, area under the curve; PDW, platelet distribution width; MPV, mean platelet volume; PDW/PLT, platelet distribution width to platelet count ratio; MPV/PLT, mean platelet volume to platelet count ratio; CI, confidence interval.

https://doi.org/10.1371/journal.pone.0189166.t002

Table 3. Association between platelet volume indices and clinicopathological factors in patients with breast cancer.

| Variables | PDW |       | MPV |       |
|-----------|-----|-------|-----|-------|
|           | Average | SD | p-value | Average | SD | p-value |
| **Age (years)** |       |     |       |       |     |       |
| <50       | 12.35 | 2.67 | 0.60 | 9.20 | 1.46 | 0.009 |
| ≥50       | 12.11 | 2.33 |       | 9.83 | 1.28 |       |
| **TS**    |       |     |       |       |     |       |
| <20       | 11.87 | 2.23 | 0.008 | 9.81 | 1.21 | 0.32  |
| ≥20       | 12.66 | 2.55 |       | 9.64 | 1.50 |       |
| **NG**    |       |     |       |       |     |       |
| 1         | 12.20 | 2.37 | 0.81  | 9.73 | 1.32 | 0.77  |
| 2, 3      | 12.11 | 2.41 |       | 9.77 | 1.33 |       |
| **LN**    |       |     |       |       |     |       |
| (–)       | 12.04 | 2.28 | 0.20  | 9.79 | 1.30 | 0.46  |
| (+)       | 12.47 | 2.62 |       | 9.65 | 1.40 |       |
| **ER**    |       |     |       |       |     |       |
| (–)       | 12.64 | 2.76 | 0.043 | 9.64 | 1.49 | 0.40  |
| (+)       | 11.98 | 2.20 |       | 9.80 | 1.26 |       |
| **PgR**   |       |     |       |       |     |       |
| (–)       | 12.50 | 2.62 | 0.039 | 9.59 | 1.44 | 0.07  |
| (+)       | 11.90 | 2.15 |       | 9.87 | 1.22 |       |
| **HER2**  |       |     |       |       |     |       |
| (–)       | 12.25 | 2.41 | 0.08  | 9.71 | 1.34 | 0.20  |
| (+)       | 11.54 | 2.05 |       | 10.01| 1.16 |       |

https://doi.org/10.1371/journal.pone.0189166.t003
counts and platelet-related markers, such as the PLR, are associated with a poor prognosis [12,13]. To the best of our knowledge, ours is the first study to demonstrate the value of PDW/P as an independent prognostic factor in breast cancer patients. Our findings may provide important supporting information to inform treatment decisions and predict treatment outcomes.

MPV and PDW are morphometric indices as well as quantitative measures of size distribution and variability of platelets; in general, the two are inversely proportional [27], and can be utilized to differentiate between hypoprotective and hyperdestructive thrombocytopenia, respectively [28]. PDW is a more specific marker of platelet activation, because it does not increase owing to platelet swelling [29]. There are pronounced contrainditory results regarding the relationship between MPV and prognosis in various cancers. Some studies found that elevated MPV levels significantly correlate with unfavorable prognoses in esophageal [17], breast [18], and hepatocellular [19] carcinoma. On the other hand, reduced MPV and MPV/P were independent predictors of negative prognosis in lung cancer patients [20, 21]. Hence, the published literature regarding the value of MVP as a prognostic factor is inconclusive. PDW may therefore be a more reliable and accurate prognostic marker than MPV in cancer patients.

The reason for the poor prognosis of patients with high PDW/P is unclear. Platelet volume is determined both during megakaryopoiesis and thrombopoiesis. PDW is an indicator

| Variables | PDW/P | MPV/P |
|-----------|-------|-------|
| Age (years) | Average | SD | p-value | Average | SD | p-value |
| <50 | 0.506 | 0.14 | 0.049 | 0.382 | 0.12 | 0.009 |
| ≥50 | 0.616 | 0.32 | 0.504 | 0.27 |
| TS | 0.603 | 0.32 | 0.502 | 0.27 | 0.27 |
| <20 | 0.602 | 0.28 | 0.466 | 0.23 |
| ≥20 | 0.599 | 0.36 | 0.487 | 0.31 |
| NG | 0.607 | 0.23 | 0.492 | 0.20 | 0.89 |
| 1 | 0.602 | 0.28 | 0.448 | 0.16 |
| 2, 3 | 0.594 | 0.24 | 0.491 | 0.21 |
| LN | 0.609 | 0.32 | 0.503 | 0.28 | 0.12 |
| (–) | 0.584 | 0.26 | 0.448 | 0.16 |
| (+) | 0.629 | 0.43 | 0.487 | 0.37 | 0.91 |
| ER | 0.594 | 0.24 | 0.491 | 0.21 |
| (–) | 0.628 | 0.39 | 0.489 | 0.33 | 0.96 |
| (+) | 0.585 | 0.22 | 0.490 | 0.19 |
| PgR | 0.619 | 0.32 | 0.499 | 0.27 | 0.21 |
| (–) | 0.511 | 0.20 | 0.442 | 0.15 |
| (+) | 0.607 | 0.23 | 0.492 | 0.20 | 0.89 |
| HER2 | 0.602 | 0.28 | 0.466 | 0.23 |
| (–) | 0.599 | 0.36 | 0.487 | 0.31 |
| (+) | 0.607 | 0.23 | 0.492 | 0.20 | 0.89 |

Abbreviations: TS, tumor size; NG, nuclear grade; LN, lymph node involvement; ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2; SD, standard deviation; p, p-value; PDW, platelet distribution width; MPV, mean platelet volume; PDW/P, platelet distribution width to platelet count ratio; MPV/P, mean platelet volume to platelet count ratio.

https://doi.org/10.1371/journal.pone.0189166.t004
of variation and heterogeneity in platelet volume; high values of this index indicates the presence of mature and immature cells simultaneously in circulation. This implies that an increase in PDW may be accompanied by abnormal thrombosis [29] and/or be the result of heterogeneous demarcation of megakaryocytes [30]. Thus, the underlying mechanism might be straightforward. Various pro-inflammatory cytokines such as tumor necrosis factor-α, interleukin-1, and interleukin-6 are upregulated concomitantly with tumor progression [31]. These cytokines promote heterogenic megakaryocytic maturation, leading to the

Table 5. Survival analyses of clinicopathological factors and platelet volume indices.

| Variables                  | Univariate analysis | Multivariate analysis |
|----------------------------|---------------------|-----------------------|
|                            | Hazard ratio (95% CI) | p-value | Hazard ratio (95% CI) | p-value |
| Age(years) (years)         |                     |          |                      |        |
| <50                        | 1                   |          |                      |        |
| ≥50                        | 0.51 (0.20–1.27)    | 0.15     |                      |        |
| Tumor size                 |                     |          |                      |        |
| <20 mm                     | 1                   | 0.00005  | 1                    | 0.017  |
| ≥20 mm                     | 4.43 (1.91–10.27)   |          | 3.24 (1.24–8.47)     |        |
| Nuclear grade              |                     |          |                      |        |
| 1                          | 1                   | 0.044    | 1                    | 0.27   |
| 2, 3                       | 2.45 (1.02–5.87)    |          | 1.72 (0.66–4.47)     |        |
| LN                         |                     |          |                      |        |
| Negative                   | 1                   | 0.029    | 1                    | 0.17   |
| Positive                   | 2.41 (1.09–5.3)     |          | 1.78 (0.78–4.1)      |        |
| ER                         |                     |          |                      |        |
| Negative                   | 1                   | 0.29     |                      |        |
| Positive                   | 0.64 (0.28–1.45)    |          |                      |        |
| PgR                        |                     |          |                      |        |
| Negative                   | 1                   | 0.84     |                      |        |
| Positive                   | 1.09 (0.49–2.41)    |          |                      |        |
| HER2                       |                     |          |                      |        |
| Negative                   | 1                   | 0.82     |                      |        |
| Positive                   | 0.87 (0.26–2.91)    |          |                      |        |
| PDW                        |                     |          |                      |        |
| <15.3                      | 1                   | 0.049    | 1                    | 0.48   |
| ≥15.3                      | 2.24 (1.0–5.03)     |          | 0.62 (0.17–2.31)     |        |
| MPV                        |                     |          |                      |        |
| <9                         | 1                   | 0.049    | 1                    | 0.18   |
| ≥9                         | 0.45 (0.2–1.0)      |          | 0.44 (0.13–1.45)     |        |
| PDW/P                      |                     |          |                      |        |
| <0.587                     | 1                   | 0.042    | 1                    | 0.021  |
| ≥0.587                     | 2.3 (1.03–5.11)     |          | 2.99 (1.18–7.57)     |        |
| MPV/P                      |                     |          |                      |        |
| <0.35                      | 1                   | 0.11     |                      |        |
| ≥0.35                      | 0.52 (0.23–1.17)    |          |                      |        |

Abbreviations: TS, tumor size; NG, nuclear grade; LN, lymph node involvement; ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2; SD, standard deviation; p, p-value; PDW, platelet distribution width; MPV, mean platelet volume; PDW/P, platelet distribution width to platelet count ratio; MPV/P, mean platelet volume to platelet count ratio; CI, confidence interval.

https://doi.org/10.1371/journal.pone.0189166.t005
production and release of immature platelets with various characteristics and sizes into the circulatory system to meet the increased demands [32]. However, additional investigations are required to better understand the reason why a high PDW/P leads to poor prognosis in breast cancer patients.

The limitations of this study include the relatively small sample size, short follow-up period and single-center design. The retrospective nature of our study may also have caused bias in terms of data selection and analysis. Despite these limitations, our study is the first to reveal that elevated PDW/P is indicative of an unfavorable prognosis in patients with localized breast cancer.

Fig 1. Kaplan-Meier analysis of DFS stratified by the platelet distribution width to platelet count ratio in patients with breast carcinoma.

https://doi.org/10.1371/journal.pone.0189166.g001
Conclusions

Despite certain limitations in our study, our data clearly indicate that an increased preoperative PDW/P measurement may represent an independent prognostic factor in patients with localized breast cancer. Measuring the PDW/P is simple, relatively inexpensive, and almost universally available using routine blood counts, making it a readily available biomarker for improved risk assessment. However, our data are preliminary and should be interpreted with caution pending validation by additional clinical studies.

Supporting information

S1 Fig. (XLSX)

Author Contributions

Conceptualization: Hideya Takeuchi, Miyuki Abe.
Data curation: Hideya Takeuchi, Yohei Takumi, Ryoji Kobayashi.
Formal analysis: Hideya Takeuchi.
Investigation: Hideya Takeuchi.
Methodology: Hideya Takeuchi, Takafumi Hashimoto, Atsushi Osoegawa.
Project administration: Hideya Takeuchi.
Resources: Hideya Takeuchi, Atsushi Osoegawa.
Software: Hideya Takeuchi.
Supervision: Hideya Takeuchi, Tatsuro Okamoto.
Validation: Hideya Takeuchi, Yohei Takumi, Michiyo Miyawaki, Tatsuro Okamoto.
Visualization: Hideya Takeuchi, Michiyo Miyawaki.
Writing – original draft: Hideya Takeuchi.
Writing – review & editing: Hideya Takeuchi, Kenji Sugio.

References

1. Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, et al. The global breast cancer burden: variation in epidemiology and survival. Clin Breast Cancer. 2005; 6: 391–401. PMID: 16381622
2. Qiu D, Katanoda K, Marugame T, Sobue T. A joinpoint regression analysis of long-term trends in cancer mortality in Japan (1958–2004). Int J Cancer. 2009; 124: 443–448. https://doi.org/10.1002/ijc.23911 PMID: 18844218
3. Kraeima J, Siesling S, Vliegen IM, Klaase JM, IJzerman MJ. Individual risk profiling for breast cancer recurrence: towards tailored follow-up schemes. Br J Cancer. 2013; 109: 866–871. https://doi.org/10.1038/bjc.2013.401 PMID: 23860534
4. Drukker CA, Bueno-de-Mesquita JM, Retèl VP, van Harten WH, van Tinteren H, Wesseling J, et al. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer. 2013; 133: 929–936. https://doi.org/10.1002/ijc.28082 PMID: 23371464
5. Kapoor JR. Platelet activation and atherothrombosis. N Engl J Med. 2008; 358:1638.
6. Stegner D, Düttting S, Nieswandt B. Mechanistic explanation for platelet contribution to cancer metastasis. Thromb Res. 2014; 133 Suppl 2:S149–S157.
7. Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. Blood. 2015; 126: 582–588. https://doi.org/10.1182/blood-2014-06-531582 PMID: 26109205
8. Takagi S, Takemoto A, Takami M, Oh-Hara T, Fujita N. Platelets promote osteosarcoma cell growth through activation of the platelet-derived growth factor receptor-Akt signaling axis. Cancer Sci. 2014; 105: 983–988. https://doi.org/10.1111/cas.12464 PMID: 24974736

9. Sulzbacher I, Birner P, Trieb K, Traxler M, Lang S, Chott A. Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma. Mod Pathol. 2003; 16: 66–71. https://doi.org/10.1097/01.MP.0000043522.76788.0A PMID: 12527715

10. Paulsson J, Sjöblom T, Micke P, Pontén F, Landberg G, Heldin CH, et al. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol. 2009; 175: 334–341. https://doi.org/10.2353/ajpath.2009.081030 PMID: 19498003

11. Kang DW, Min DS. Platelet derived growth factor increases phospholipase D1 but not phospholipase D2 expression via NFκB signaling pathway and enhances invasion of breast cancer cells. Cancer Lett. 2010; 294: 125–33. https://doi.org/10.1016/j.canlet.2010.01.031 PMID: 20188462

12. Takeuchi H, Fukuyama S, Kubo N, Hiroshige S, Kawanaka H, Yoshikawa Y, et al. The prognostic significance of the preoperative platelet-lymphocyte ratio in Japanese patients with localized breast cancer. Adv Breast Cancer Res. 2016; 5: 49–57.

13. Takeuchi H, Kawanaka H, Fukuyama S, Kubo N, Hiroshige S, Yano T. Comparison of the prognostic values of preoperative inflammation-based parameters in patients with breast cancer. PLoS One. 2017; 12: e0177137. https://doi.org/10.1371/journal.pone.0177137 PMID: 28489884

14. Martin JF, Bath PM, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet. 1991; 338: 1409–1411. PMID: 1683417

15. Gasparayan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation. Curr Pharm Des. 2011; 17: 47–58. PMID: 21247392

16. Kaito K, Otsubo H, Usui N, Yoshida M, Tanno J, Kurihara E, et al. Platelet size deviation width, platelet large cell ratio, and mean platelet volume have sufficient sensitivity and specificity in the diagnosis of immune thrombocytopenia. Br J Haematol. 2005; 128: 698–702 https://doi.org/10.1111/j.1365-2141.2004.05357.x PMID: 15725092

17. Zhang F, Chen Z, Wang P, Hu X, Gao Y, He J. Combination of platelet count and mean platelet volume ratio (COP-MPV) predicts postoperative prognosis in both resectable early and advanced stage esophageal squamous cell cancer patients. Tumour Biol. 2016; 37: 9323–9331. https://doi.org/10.1007/s13277-015-4774-3 PMID: 26779631

18. Gu M, Zhai Z, Huang L, Zheng W, Zhou Y, Zhu R, et al. Pre-treatment mean platelet volume associates with worse clinicopathologic features and prognosis with invasive breast cancer. Breast Cancer 2016; 23: 752–760. https://doi.org/10.1007/s12377-015-4774-3 PMID: 26730638

19. Cho SY, Yang JJ, You E, Kim BH, Shim J, Lee HJ et al. Mean platelet volume/platelet count ratio in hepatocellular carcinoma. Platelets. 2013; 24: 375–377. https://doi.org/10.1016/j.plt.2012.07.0106 PMID: 22835043

20. Inagaki N, Kibata K, Yamashita T, Nomura S. Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-small cell lung cancer. Lung Cancer. 2014; 83: 97–101. https://doi.org/10.1016/j.lungcan.2013.08.020 PMID: 24189108

21. Kumagai S, Tokuno J, Ueda Y, Marumo S, Shoji T, Nishimura T, et al. Prognostic significance of preoperative mean platelet volume in resected non-small-cell lung cancer. Mol Clin Oncol. 2015; 3: 197–201. https://doi.org/10.3892/mco.2014.436 PMID: 25469294

22. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011; 22: 1736–1747. https://doi.org/10.1093/annonc/mdr304 PMID: 21709140

23. Noh H, Eom M, Han A. Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer. 2013; 16: 55–59. https://doi.org/10.4048/jbc.2013.16.1.55 PMID: 23593082

24. Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013; 48: 452–458. https://doi.org/10.1038/bmt.2012.244 PMID: 23208313

25. Miyazono K, Yuki K, Takaku F, Wernstedt C, Kanzaki T, Olofsson A, et al. Latent forms of TGF-beta: structure and biology. Ann N Y Acad Sci. 1990; 593: 51–58. PMID: 2375598

26. Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagwara K, et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature. 1989; 338: 557–562. https://doi.org/10.1038/338557a0 PMID: 2467210

27. Shen J, Ran ZH, Zhang Y, Cai Q, Yin HM, Zhou XT, et al. Biomarkers of altered coagulation and fibrinolysis as measures of disease activity in active inflammatory bowel disease: a gender-stratified, cohort study.
28. De Luca G, Venegoni L, Iorio S, Secco GG, Cassetti E, Verdoia M, et al. Platelet distribution width and the extent of coronary artery disease: Results from a large prospective study. Platelets. 2010; 21:508–514. https://doi.org/10.3109/09537104.2010.494743 PMID: 20874431

29. Vagdatli E, Gounari E, Lazaridou E, Katsibourlia E, Tsikopoulou F, Labrianou I. Platelet distribution width: a simple, practical and specific marker of activation of coagulation. Hippokratia. 2010; 14: 28–32. PMID: 20411056

30. Matsuo K, Tang SH, Sharifi b, Rubin SA, Schreck R, Fagin JA. Growth factor production by human thyroid carcinoma cells: abundant expression of a platelet-derived growth factor-B-like protein by a human papillary carcinoma cell line. J Clin Endocrinol Metab. 1993; 77: 996–1004. https://doi.org/10.1210/jcem.77.4.8408476 PMID: 8408476

31. Kayacan O, Karnak D, Beder S, Güllü E, Tutkak H, Senler FC, et al. Impact of TNF-alpha and IL-6 levels on development of cachexia in newly diagnosed NSCLC patients. Am J Clin Oncol. 2006; 29: 328–335. https://doi.org/10.1097/01.coc.0000221300.72657.e0 PMID: 16891858

32. Kaushansky K. Growth factors and hematopoietic cell fate. A new feature: controversies in hematology. Blood. 1998; 92: 345–354.